Verge Genomics Presents Preclinical Data Supporting Broad-Spectrum Potential of Its Novel, Oral Antiviral at the 31st European Congress of Clinical Microbiology & Infectious Diseases
Retrieved on:
Mercredi, juillet 7, 2021
Health, Infectious diseases, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Coronaviridae, Sarbecovirus, Antiviral drug, Severe acute respiratory syndrome, COVID-19 drug repurposing research, GC376, the Preclinical Study, PIKfyve, Verge Genomics, THE PRECLINICAL STUDY, PIKFYVE, VERGE GENOMICS
The results will be presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) online meeting being held July 9-12, 2021.
Key Points:
- The results will be presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) online meeting being held July 9-12, 2021.
- There remains an urgent need for oral antiviral treatments for SARS-CoV-2 and its variants, said Alice Zhang, CEO and Co-Founder of Verge Genomics.
- Verge has demonstrated potent antiviral activity in vitro and improvement of SARS-CoV-2-induced pathology in vivo by the PIKfyve inhibitor, VRG101.
- Verge is focused on developing therapeutics for serious genetic diseases using human genomics and machine learning.